Protocol Ledger

NCT07164833 · Phase II · RECRUITING

A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE)

Interventional Phase II clinical trial protocol NCT07164833 sponsored by Bilix Co in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-26 Enrollment: 50 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07164833
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)50 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07164833
Protocol FieldVerified Registry Value
NCT IdentifierNCT07164833
Consolidated Lead SponsorBilix Co
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment50 participants (ESTIMATED)
Registered Start Date2025-08-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07164833
Hospital Research SiteLocationSite Profile
Seoul National University Bundang HospitalSeongnam, South KoreaOpen Hospital Dossier ->
Korea University Anam HospitalSeoul, South KoreaOpen Hospital Dossier ->
Seoul National University HospitalSeoul, South KoreaOpen Hospital Dossier ->
Severance HospitalSeoul, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI